Page last updated: 2024-10-30

mecamylamine and Attachment Loss, Periodontal

mecamylamine has been researched along with Attachment Loss, Periodontal in 1 studies

Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Research Excerpts

ExcerptRelevanceReference
"The results indicate that nicotine enhances the susceptibility to periodontitis via nicotinic acetylcholine receptors, which may act by suppressing protective immune responses through the cholinergic anti-inflammatory pathway."7.75Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis. ( Breivik, T; Gjermo, P; Gundersen, Y; Opstad, PK; von Hörsten, S, 2009)
"The results indicate that nicotine enhances the susceptibility to periodontitis via nicotinic acetylcholine receptors, which may act by suppressing protective immune responses through the cholinergic anti-inflammatory pathway."3.75Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis. ( Breivik, T; Gjermo, P; Gundersen, Y; Opstad, PK; von Hörsten, S, 2009)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Breivik, T1
Gundersen, Y1
Gjermo, P1
von Hörsten, S1
Opstad, PK1

Other Studies

1 other study available for mecamylamine and Attachment Loss, Periodontal

ArticleYear
Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis.
    Journal of periodontal research, 2009, Volume: 44, Issue:3

    Topics: Alveolar Bone Loss; Animals; Corticosterone; Disease Susceptibility; Immunity; Interleukin-10; Lipop

2009